ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "registry"

  • Abstract Number: 274 • 2018 ACR/ARHP Annual Meeting

    Socioeconomic Disparities in Disease Activity in Patients with Rheumatoid Arthritis

    Lei Zhu1, Evelyn Talbott2 and Larry W. Moreland1, 1Division of Rheumatology and Clinical Immunology, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, 2Epidemiology, University of Pittsbugh, Pittsburgh, PA

    Background/Purpose: To develop a methodology for well-defined rheumatoid arthritis (RA) measurement as an outcome and provide a clear definition of social determinants related to disease…
  • Abstract Number: 549 • 2018 ACR/ARHP Annual Meeting

    Unmet Treat-to-Target Goals with Available Targeted Immunomodulators in the Management of Rheumatoid Arthritis: Real World Evidence from the Corrona Registry

    Dimitrios A. Pappas1,2, Namita Tundia3, Ying Shan2, Heather J Litman2 and Joel Kremer4, 1Columbia University, New York, NY, 2Corrona, LLC, Southborough, MA, 3AbbVie Inc., North Chicago, IL, 4Albany Medical College and the Center for Rheumatology, Albany, NY

    Background/Purpose: Targeted immunomodulators (TIMs) have revolutionized the therapy of RA and made low disease activity (LDA) a realistic goal for patients. Given the multiple therapy…
  • Abstract Number: 580 • 2018 ACR/ARHP Annual Meeting

    Clinical Effectiveness of Tofacitinib 11mg Once Daily (QD) Versus Tofacitinib 5mg Twice Daily (BID) in the Corrona US RA Registry

    Stanley Cohen1, Heather J Litman2, Connie Chen3, Tatjana Lukic3, Ann Madsen3, Liza Takiya4, Kimberly J Dandreo2, Taylor Blachley2 and Jeffrey Greenberg2, 1Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2Corrona LLC, Waltham, MA, 3Pfizer Inc, New York, NY, 4Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA, originally approved at 5 mg twice daily (BID). In 2016, an extended-release…
  • Abstract Number: 606 • 2018 ACR/ARHP Annual Meeting

    Similiar Efficacy of Tofacinitib on Disease Activity in Rheumatoid Arthritis Patients with and without Previous Biologicals; Results from the Turkbio Regıstry

    Berrin Zengin1, Nevsun Inanc2, Servet Akar3, Gerçek Can1, Ediz Dalkiliç4, Abdurrahman Tufan5, Soner Senel6, Suleyman Serdar Koca7, Handan Yarkan1, Yavuz Pehlivan8, Zeynep Erturk9, Berna Goker5, Haner Direskeneli2, Merih Birlik1, Nurullah Akkoc10 and Fatos Onen1, 1Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, 2Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, 3Faculty of Medicine, Department of Rheumatology, Izmir Katip Celebi University, Izmir, Turkey, 4Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, 5Internal Medicine-Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey, 6Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, 7Rheumatology, Firat University Faculty of Medicine, Elazığ, Turkey, 8Rheumatology, Uludag University, Faculty of Medicine, Bursa, Turkey, 9Rheumatology, Marmara University Faculty of Medicine, istanbul, Turkey, 10Rheumatology, İzmir, Turkey, İzmir, Turkey

    Background/Purpose: Tofacitinib, a JAK3 inhibitor has been used to treat patients with rheumatoid arthritis (RA) in Turkey since 2015. The aim of this study was…
  • Abstract Number: 628 • 2018 ACR/ARHP Annual Meeting

    Longitudinal Changes in Relative Market Share Proportions of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Descriptive Data from the Ontario Best-Practice Research Initiative Database

    Elliot Hepworth1, Mohammad Movahedi2, Emmanouil Rampakakis3, Reza Mirza1, Arthur Lau4, Angela Cesta5, Janet E. Pope6 and Claire Bombardier7, 1Department of Internal Medicine, McMaster University, Hamilton, ON, Canada, 2JSS Medical Research, St-Laurent, QC, Canada, 3JSS Medical Research, Montreal, QC, Canada, 450 Charlton Avenue East, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, 5Ontario Best Practices Research Initiative, University Health Network, Toronto, ON, Canada, 6Department of Medicine, University of Western Ontario, London, ON, Canada, 7Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada

    Background/Purpose: For patients with Rheumatoid Arthritis (RA) who do not achieve adequate clinical response with combined conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), the next…
  • Abstract Number: 629 • 2018 ACR/ARHP Annual Meeting

    Real-World Use of Tofacitinib Compared with Tumor Necrosis Factor Inhibitors in a Cohort of 211 Patients with Rheumatoid Arthritis: Data from a Drug-Based Registry Study in Taiwan

    Song-Chou Hsieh1, Yi-Hsing Chen2, Wei-Sheng Chen3, Wen-Chan Tsai4, Jui-Chieh Hu5, Hsiang-Cheng Chen6, Jack Mardekian7 and Chacun Lai8, 1National Taiwan University Hospital, Taipei, Taiwan, 2Taichung Veterans General Hospital, Taichung City, Taiwan, 3Taipei Veterans General Hospital, Taipei, Taiwan, 4Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 5Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, 6National Defense Medical Center & Tri-Services General Hospital, Taipei, Taiwan, 7Pfizer Global Biometrics & Data Management, NY, NY, 8Pfizer PFE Limited, New Taipei, Taiwan

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib was approved in December 2014 for RA under Taiwan’s National Health…
  • Abstract Number: 1641 • 2018 ACR/ARHP Annual Meeting

    Spa-Net: A Disease-Specific Integrated Ehealth System and Quality Registry for Spondyloarthritis in Daily Practice in the Netherlands

    Casper Webers1,2, Esther Beckers1,2, Yvonne van Eijk-Hustings1,2, Harald Vonkeman3, Mart van de Laar3, Piet van Riel4, Monique Efde5, Annelies Boonen1,2 and Astrid van Tubergen1,2, 1Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 2Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, Netherlands, 3Department of Rheumatology, Medisch Spectrum Twente, Enschede, Netherlands, 4Department of Rheumatology, Bernhoven, Uden, Netherlands, 5Department of Rheumatology, VieCuri Medical Center, Venlo, Netherlands

    Background/Purpose: Regular and personalised monitoring of disease activity, functioning, medication use and side effects is essential to improve and maintain patients’ health-related quality of life…
  • Abstract Number: 471 • 2017 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis Patients Resistant to Biologic Therapy, Are They Different?

    Adeeba Al-Herz1, Aqeel Ghanem2, Khulood Saleh3, Adel Al-Awadhi4, Waleed Al-Kandari3, Eman Hasan5, Mohammad Hussain5, Ibrahim Nahar2, Fatemah Abutiban6, Ahmad Alenizi6, Yaser Ali2, Ali Aldei1, Hebah Alhajeri2, Sawsan Hayat2, Ahmad Khadrawy3, Ammad Fazal3, Khaled Mokaddem1, Agaz Zaman2, Ghada Mazloum2, Youssef Bartella1, Sally Hamed1, Ramia Alsouk6 and Ahmed Al-Saber7, 1Rheumatology, Al-Amiri Hospital, Kuwait city, Kuwait, 2Rheumatology, Mubarak Al-Kabeer Hospital, Hawally, Kuwait, 3Rheumatology, Farwania Hospital, Farwania, Kuwait, 4Faculty of Medicine, Kuwait, Kuwait, 5Al-Amiri Hospital, Kuwait city, Kuwait, 6Rheumatology, Jahra Hospital, Jahra, Kuwait, 7Department of Mathematics, Kuwait Technical College, Kuwait city, Kuwait

    Background/Purpose: Patients with rheumatoid arthritis (RA) may fail to respond to biologic therapy. We study patients who are resistant to different classes of biologic agents…
  • Abstract Number: 1423 • 2017 ACR/ARHP Annual Meeting

    Patterns of Prednisone Use in US Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine Clinical Practice

    Dimitrios A. Pappas1, Carol J. Etzel2, Jennie Best3, Steve Zlotnick3, Taylor Blachley2, Gioia Persuitte2 and Joel Kremer4, 1Columbia University, New York, NY, 2Corrona, LLC, Southborough, MA, 3Genentech, Inc., South San Francisco, CA, 4Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: There are limited data regarding the impact of tocilizumab (TCZ) treatment on prednisone use in patients with rheumatoid arthritis (RA). The objective of this…
  • Abstract Number: 1472 • 2017 ACR/ARHP Annual Meeting

    Body Mass Index Does Not Affect Response to Rituximab in Patients with Rheumatoid Arthritis: Results from Turkbio Registry

    Suleyman Serdar Koca1, Ahmet Karatas2, Burak Oz3, Ediz Dalkilic4, Gerçek Can5, Yavuz Pehlivan6, Ayten Yazici7, Nevsun Inanc8, Ayse Cefle9, Zeypen Erturk10, Servet Akar11, Soner Senel12, Merih Birlik13, Nurullah Akkoc14 and Fatos Onen15, 1Department of Rheumatology, Firat University School of Medicine, Elazig, Turkey, 2Department of Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, 3Rheumatology, Firat University, School of Medicine, Rheumatology, Elazig, Turkey, 4Department of Internal Medicine, Division of Rheumatology, Uludag University, School of Medicine, Rheumatology, Bursa, Turkey, 5Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, 6Department of Rheumatology, Uludag University, Bursa, Turkey, 7Rheumatology, Kocaeli University, Kocaeli, Turkey, 8Departement of İnternal Medicine, Division of Rheumatology, Marmara University, Istanbul, Turkey, 9Rheumatology, Kocaeli University, School of Medicine, Rheumatology, Kocaeli, Turkey, 10Department of Rheumatology, Marmara Univeristy School of Medicine, Istanbul, Turkey, 11Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, 12Rheumatology, Kayseri Erciyes University, School of Medicine, Rheumatology, Kayseri, Turkey, 13Department of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, 14Rheumatology, Private Practice, Rheumatology, İzmir, Turkey, 15Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey

    Background/Purpose: Adipose tissue produces several inflammatory mediators. Thus, obesity affects the disease course and the responses to the anti-rheumatic agents in inflammatory diseases. Several previous…
  • Abstract Number: 2366 • 2017 ACR/ARHP Annual Meeting

    High Uric Acid As a Risk Factor for Cardiovascular Diseases in Rheumatoid Arthritis Patients

    Adeeba Al-Herz1, Ali Aldei1, Khulood Saleh2, Adel Al-Awadhi3, Waleed Al-Kandari2, Eman Hasan4, Aqeel Ghanem5, Mohammad Hussain4, Ibrahim Nahar5, Fatemah Abutiban6, Ahmad Alenizi6, Yaser Ali5, Hebah Alhajeri5, Sawsan Hayat5, Ahmad Khadrawy2, Ammad Fazal2, Khaled Mokaddem1, Agaz Zaman5, Ghada Mazloum5, Youssef Bartella1, Sally Hamed1, Ramia Alsouk6 and Ahmed Al-Saber7, 1Rheumatology, Al-Amiri Hospital, Kuwait city, Kuwait, 2Rheumatology, Farwania Hospital, Farwania, Kuwait, 3Faculty of Medicine, Kuwait, Kuwait, 4Al-Amiri Hospital, Kuwait city, Kuwait, 5Rheumatology, Mubarak Al-Kabeer Hospital, Hawally, Kuwait, 6Rheumatology, Jahra Hospital, Jahra, Kuwait, 7Department of Mathematics, Kuwait Technical College, Kuwait city, Kuwait

    Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular diseases (CVD). It is unclear whether an elevated serum uric acid (UA) further increases…
  • Abstract Number: 2665 • 2017 ACR/ARHP Annual Meeting

    Mortality in an Early Diffuse Cutaneous Systemic Sclerosis Cohort—Data from the Prospective Registry for Early Systemic Sclerosis

    Tracy M. Frech1, Shervin Assassi2, Elana J. Bernstein3, Flavia V. Castelino4, Robyn T. Domsic5, Jessica K. Gordon6, Faye Hant7, Monique Hinchcliff8, Bernie LaSalle9, Victoria K. Shanmugam10, Virginia D. Steen11 and Dinesh Khanna12, 1Division of Rheumatology, University of Utah, Salt Lake City, UT, 2University of Texas McGovern Medical School, Houston, TX, 3Department of Medicine, Division of Rheumatology, Columbia University, New York, NY, 4Rheumatology, Allergy, Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 5Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 6Rheumatology, Hospital for Special Surgery, New York, NY, 7Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 8Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 9University of Utah, Salt Lake City, UT, 10Rheumatology, The George Washington University, Washington, DC, 11Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, 12University of Michigan, Ann Arbor, MI

    Background/Purpose: The Prospective Registry of Early Systemic Sclerosis (PRESS) cohort is an early diffuse cutaneous systemic sclerosis (dcSSc) that provides an opportunity to assess the…
  • Abstract Number: 2588 • 2016 ACR/ARHP Annual Meeting

    The Real World Comparative Safety of Certolizumab Pegol (CZP) As Compared to Other TNFi in a National US Cohort

    Leslie R. Harrold1,2, Heather J. Litman1, Katherine C. Saunders1, Kimberly J. Dandreo1, Bernice Gershenson2, Jeffrey D. Greenberg1,3, Robert Low4, Jeffrey Stark4, Robert Suruki4, Srihari Jaganathan4 and Mohamed Yassine4, 1Corrona, LLC, Southborough, MA, 2University of Massachusetts Medical School, Worcester, MA, 3NYU School of Medicine, New York, NY, 4UCB Pharma, Smyrna, GA

    Background/Purpose: To examine the association of cardiovascular, malignant and serious infection events (SIEs) with certolizumab pegol (CZP) use as compared to other TNFi agents in…
  • Abstract Number: 2618 • 2016 ACR/ARHP Annual Meeting

    Risk Factors of Severe Infections in Patients with Rheumatoid Arthritis Treated with Tocilizumab in the French Registry Regate (REGISTRY –ROACTEMRA)

    Jacques Morel1,2, Arnaud CONSTANTIN3, Gabriel Baron4, Emmanuelle Dernis5, Rene-Marc Flipo6,7, Stephanie Rist Bouillon8, Bernard Combe9, Jacques-Eric Gottenberg10, Thierry Schaeverbeke11,12, Martin Soubrier13, Olivier Vittecoq14, Maxime Dougados15, Alain Saraux16, Xavier Mariette17, Philippe Ravaud18 and Jean Sibilia19, 1Montpellier University Hospital, Montpellier, France, 2Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, 3Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, 4Hôpital Hôtel Dieu, Paris, France, 5Service de Rhumatologie, Centre Hospitalier, Le Mans, France, 6Rheumatology, Hopital R Salengro CHRU, Lille, France, 7Rheumatology, University Hospital, Lille, France, 8Rhumatologie, Hopital La Source, La Source, France, 9Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 10Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 11Bordeaux University Hospital, Bordeaux, France, 12Rheumatology, CHU Bordeaux, Bordeaux, France, 13Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, 14Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, 15Paris Descartes University, Paris, France, 16Rheumatology, Brest University Medical School Hospital, Brest, France, 17Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France, 18Centre d’Épidémiologie Clinique, AP-HP (Assistance Publique des Hôpitaux de Paris), Hôpital Hôtel Dieu, Paris, France, 19Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France

    Background/Purpose: Observational studies have already reported the risk of serious infections in rheumatoid arthritis (RA) treated with tocilizumab but in limited samples. The aim of…
  • Abstract Number: 2625 • 2016 ACR/ARHP Annual Meeting

    Safety of Multiple Retreatments with Rituximab  in Real Life: Long Term Registry Data from 1984 Patients with Rheumatoid Arthritis

    Jacques-Eric Gottenberg1, Philippe Ravaud2, Thomas Bardin3, Alain Cantagrel4, Bernard Combe5, Maxime Dougados6, RENE MARC FLIPO7, Olivier Vittecoq8, Thierry Schaeverbeke9, Isabelle Pane10, Jean Sibilia11, Xavier Mariette12 and on behaf of all of the investigators of the AIR registry and of the French Society of Rheumatology , 1Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 2Epidemiology, Hotel Dieu, PARIS, France, 3Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, 4Rheumatology, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Purpan Teaching Hospital, Toulouse, France, 5Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 6Rheumatology, Paris Descartes University, Paris, France, 7Rheumatology, Department of Rheumatology, CHU Teaching Hospital Lille, France., Lille, France, 8INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, 9Rheumatology, CHU Bordeaux, Bordeaux, France, 10Epidemiology, Hotel Dieu, Paris, France, 11Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 12Institut National de la Santé et de la Recherche Médicale, Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France

    Background/Purpose: Data are very limited concerning the safety of multiple retreatments with rituximab (RTX) in rheumatoid arthritis in common practice. Methods: This is a multicenter…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology